News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zafgen's Obesity Drug Targets Body, Not the Mind; With an Ex-Novartis AG (NVS) Exec in Charge, Co. May Have an Edge Over Its Competitors


8/27/2013 7:44:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Imagine a weight-loss drug that not only helps you shed a few pounds, but does so without asking you to diet or exercise. In an industry dogged by safety concerns, a private U.S. company is betting on a new approach to deliver just such a treatment that could end up being the first billion-dollar diet drug. Initial trials show that Zafgen Inc, run by a former Novartis AG executive, might have an edge over its competitors, especially since its experimental drug has so far not demonstrated any major safety concerns.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES